TrialDiabetes, obesity & metabolism2022

Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.

Julie Dubourg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.